Ocular TherapeutixOCUL
About: Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
Employees: 267
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
115% more repeat investments, than reductions
Existing positions increased: 56 | Existing positions reduced: 26
8.68% more ownership
Funds ownership: 83.82% [Q1] → 92.5% (+8.68%) [Q2]
1% more funds holding
Funds holding: 146 [Q1] → 148 (+2) [Q2]
6% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 36
13% less funds holding in top 10
Funds holding in top 10: 8 [Q1] → 7 (-1) [Q2]
13% less capital invested
Capital invested by funds: $1.13B [Q1] → $980M (-$152M) [Q2]
56% less call options, than puts
Call options by funds: $1.63M | Put options by funds: $3.72M
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
Scotiabank Greg Harrison 70% 1-year accuracy 14 / 20 met price target | 97%upside $22 | Sector Outperform Initiated | 16 Oct 2024 |
HC Wainwright & Co. Yi Chen 36% 1-year accuracy 35 / 97 met price target | 26%upside $14 | Buy Reiterated | 16 Oct 2024 |
Baird Colleen Kusy 20% 1-year accuracy 3 / 15 met price target | 52%upside $17 | Outperform Maintained | 8 Aug 2024 |
HC Wainwright & Co. Yi Chen 36% 1-year accuracy 35 / 97 met price target | 26%upside $14 | Buy Reiterated | 1 Aug 2024 |
Financial journalist opinion
Based on 6 articles about OCUL published over the past 30 days
